Shares Magazine
12.00p-0.75 (-5.88%)19 Apr 2024, 18:27
Jump to:
Redx Pharma PLC Fundamentals
| Company Name | Redx Pharma PLC | Last Updated | 2024-04-19 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 388.986 m | Market Cap | £46.68 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.10 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.6897 | Debt Equity Ratio | 0.3797 |
| Asset Equity Ratio | 7.6411 | Cash Equity Ratio | 5.3925 |
| Quick Ratio | 1.0815 | Current Ratio | 1.11 |
| Price To Book Value | 14.7929 | ROCE | 0 |
Redx Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Redx Pharma PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £1.94 m | £2.70 m | £3.33 m |
| Intangible Assets | £394,000.00 | £400,000.00 | £405,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £2.33 m | £3.10 m | £3.73 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £4.63 m | £4.59 m | £5.58 m |
| Cash & Equivalents | £18.09 m | £53.85 m | £29.55 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £25.64 m | £62.48 m | £39.55 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £21.01 m | £27.20 m | £9.59 m |
| Creditors after 1 year | £1.27 m | £1.95 m | £16.82 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £22.28 m | £29.16 m | £26.41 m |
| Net assets | £3.35 m | £33.32 m | £13.13 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £3.35 m | £3.35 m | £2.75 m |
| Share Premium | £99.50 m | £99.50 m | £66.30 m |
| Profit / Loss | -£32.79 m | -£17.80 m | -£21.44 m |
| Other Equity | £3.35 m | £33.32 m | £13.13 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £3.35 m | £33.32 m | £13.13 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.28 | £0.06 | £0.56 |
| Debt-to-Equity | £0.38 | £0.06 | £1.28 |
| Assets / Equity | 7.6411 | 7.6411 | 7.6411 |
| Cash / Equity | 5.3925 | 5.3925 | 5.3925 |
| EPS | -£0.10 | -£0.06 | -£0.08 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£34.75 m | -£8.47 m | -£21.38 m |
| Cashflow before financing | -£35.56 m | £24.51 m | £2.76 m |
| Increase in Cash | -£35.76 m | £24.27 m | £2.01 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £4.20 m | £18.69 m | £10.04 m |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£33.82 m | -£16.27 m | -£19.75 m |
| Pre-Tax profit | -£32.79 m | -£17.80 m | -£21.44 m |
Redx Pharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in the UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration, and Research and preclinical development services. |
| Latest Interim Date | 17 May 2023 |
| Latest Fiscal Year End Date | 15 Dec 2023 |
Redx Pharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-06-01 | Mr. Iain Gladstone Ross | Non-Executive Director,Chairman |
| 2018-02-19 | Dr. Frank Murdoch Armstrong | Non-Executive Director,Chairman |
| 2024-02-17 | Mr. Peter Eric Presland | Non-Executive Director |
| 2018-02-19 | Mr. Norman Molyneux | Non-Executive Director |
| 2018-02-19 | Dr. Neil David Murray | Executive Director,Chief Executive Officer |
| 2018-02-19 | Dr. Peter Jackson | Non-Executive Director |
| 2017-03-30 | Dr. Derek Lindsay | Executive Director,Chief Operating Officer |
| 2017-03-30 | Mr. Philip John Tottey | Executive Director,Chief Financial Officer |
| 2017-04-20 | Mr. Peter McPartland | Non-Executive Director |
| 2024-02-17 | Dr. Bernhard Jurgen Kirschbaum | Non-Executive Director |
| 2024-02-17 | Dr. Jane Veronica Griffiths | Non-Executive Director,Chairman |
| 2020-03-17 | Mr. Dominic Nicholas Jackson | Executive Director,Chief Financial Officer |
| 2024-04-18 | Mrs. Lisa Mary Whewell Anson | Executive Director,Chief Executive Officer |
| 2021-03-02 | Dr. James Robert Mead | Executive Director,Chief Financial Officer |
| 2024-02-17 | Mrs. Sarah Gordon Wild | Non-Executive Director |
| 2024-02-17 | Dr. Robert Andrew Donald Scott, M.D. | Non-Executive Director |
Redx Pharma PLC Contact Details
| Company Name | Redx Pharma PLC |
|---|---|
| Address | Block 33, Mereside, Alderley Park, Macclesfield, SK10 4TG |
| Telephone | +44 1625469900 |
| Website | https://www.redxpharma.com |
Redx Pharma PLC Advisors
| Auditor | RSM |
|---|---|
| Phone | +44 1618304000 |
| Fax | +44 1618304001 |
| Stockbroker | WG Partners |
|---|
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Nominated Adviser | Cantor Fitzgerald Europe |
|---|---|
| Phone | +44 2078947895 |
| Stockbroker | Cantor Fitzgerald Europe |
|---|---|
| Phone | +44 2078947895 |
| Solicitor | DWF LLP |
|---|---|
| Phone | +44 1612283702 |
| Fax | +44 1618352407 |
| Registrar | Equiniti Ltd. |
|---|---|
| Phone | +44 1214157082 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Mondi PLC | 1,504.50 | 9.30 |
| Darktrace PLC | 476.20 | 3.88 |
| Energean PLC | 1,019.00 | 3.87 |
| Close Brothers Group PLC | 453.20 | 3.09 |
| Ashmore Group PLC | 184.80 | 2.44 |
| Hochschild Mining PLC | 154.60 | 2.38 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Smith (Ds) PLC | 358.60 | -10.26 |
| Man Group PLC | 251.00 | -6.55 |
| Marshalls PLC | 257.50 | -4.10 |
| Foresight Group Holdings Limited | 440.00 | -3.93 |
| Dr. Martens PLC | 67.30 | -3.65 |
| Allianz Technology Trust PLC | 328.50 | -3.10 |